Show your appreciation. Take 25% off select tests until 06/20 with code FATHERSDAY at checkout.SHOP TESTS

Meet Our Leading Medical Researcher in Rheumatoid Arthritis Early Detection and Treatment — Dr. Kevin Deane, MD, Ph.D.

Published:
Sep 2, 2020
-
Updated:
Nov 24, 2020
-
Contributor:
-
2 minutes

Medically reviewed by

Jani Tuomi
Jani TuomiJani Tuomi
Co-founder at imaware™
Jani is the co-founder of imaware™. After having loved ones fall ill to preventable conditions, Jani became passionate about proactive healthcare which led him to engage with world leading doctors to produce an at-home solution.
Learn about our content process
Learn about our content process

Kevin Deane, MD, Ph.D., is an Associate Professor at University of Colorado Denver, Anschutz Medical Campus.

Dr. Deane’s research is focused primarily on the preclinical period of the disease rheumatoid arthritis (RA), and he is currently investigating how genetics and environmental factors influence the early development of RA

Dr. Deane’s research is focused primarily on the preclinical period of the disease rheumatoid arthritis (RA), and he is currently involved as a co-investigator in a multi-centered study investigating how genetics and environmental factors influence the early development of RA. A variety of autoimmune diseases have a ‘preclinical’ period of development where blood or other tests can show abnormalities in the immune system sometimes years prior to an individual actually feeling sick from the disease.

imaware™ is excited to have Dr. Deane, one of the leading experts on pre-clinical rheumatoid arthritis, and the Anti-CCP biomarker, on our Medical Sciences team. Dr. Deane has helped review and validate our platform, and the patient-facing report to ensure all scenarios and recommendations align with clinical practices and guidelines.

Dr. Deane is the Principal Investigator on an NIH-sponsored clinical trial for the prevention of RA that is entitled ‘Strategy for the Prevention of RA, or ‘StopRA’. For this trial, individuals (including relatives of patients with RA) who have blood markers suggesting they are at high-risk of developing RA themselves within several years are being selected. These individuals will then be given a drug to see if RA can be stopped before even the first signs of arthritis develop. Dr. Deane and his team have great hope that this trial will be a large part of a major change in how we approach RA and other autoimmune diseases where instead of just treating these diseases once people become sick, we will instead try and prevent them during an asymptomatic phase.

Besides his work in rheumatic research and clinical care, Dr. Kevin Deane is Associate Professor of Medicine at the University of Colorado School of Medicine with a primary appointment within the Division of Rheumatology. His teaching focus is on the evaluation and treatment of rheumatic diseases, as well as the pathophysiology of rheumatic diseases. Dr. Deane received his Ph.D. in Clinical Science from the University of Colorado, SOM, and has authored or contributed to over 30 pubmed cited articles.

Get your at-home
health test

Get a complete picture of your health and wellness quickly & conveniently from the comfort of your own home.

• Physician reviewed
• Free shipping
• Results in 7 days
Shop Tests
Get your at-home
Rheumatoid Arthritis Test

Measure three key biomarkers and detect the asymptomatic signs of rheumatoid arthritis quickly and conveniently from the comfort of home.

• Physician reviewed
• Free shipping
• Results in 7 days
Order Test
Was this article helpful?
Thanks for your input!
Oops! Something went wrong while submitting the form.
Oops! Something went wrong while submitting the form.